Rabeprazole 20 mg twice a day for 90-day period treatment
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postnasal Drainage
Conditions
Postnasal Drainage
Trial Timeline
Jun 1, 2002 → Dec 1, 2007
NCT ID
NCT00199953About Rabeprazole 20 mg twice a day for 90-day period treatment
Rabeprazole 20 mg twice a day for 90-day period treatment is a phase 2 stage product being developed by Eisai for Postnasal Drainage. The current trial status is completed. This product is registered under clinical trial identifier NCT00199953. Target conditions include Postnasal Drainage.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00199953 | Phase 2 | Completed |